112 related articles for article (PubMed ID: 35016922)
1. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.
Wahi A; Jain P; Sinhari A; Jadhav HR
Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):675-702. PubMed ID: 37615708
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting stromal Class I HDACs curbs pancreatic cancer progression.
Liang G; Oh TG; Hah N; Tiriac H; Shi Y; Truitt ML; Antal CE; Atkins AR; Li Y; Fraser C; Ng S; Pinto AFM; Nelson DC; Estepa G; Bashi S; Banayo E; Dai Y; Liddle C; Yu RT; Hunter T; Engle DD; Han H; Von Hoff DD; Downes M; Evans RM
Nat Commun; 2023 Dec; 14(1):7791. PubMed ID: 38057326
[TBL] [Abstract][Full Text] [Related]
3. Protein Arginine Methyltransferases in Pancreatic Ductal Adenocarcinoma: New Molecular Targets for Therapy.
Bhandari K; Ding WQ
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612768
[TBL] [Abstract][Full Text] [Related]
4. Precision medicine in pancreatic cancer: treating every patient as an exception.
Herbst B; Zheng L
Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):805-810. PubMed ID: 31511204
[TBL] [Abstract][Full Text] [Related]
5. Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans.
Telisnor G; DeRemer DL; Frimpong E; Agyare E; Allen J; Ricks-Santi L; Han B; George T; Rogers SC
J Natl Med Assoc; 2023 Apr; 115(2):164-174. PubMed ID: 36801148
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic control of pancreatic cancer metastasis.
Krauß L; Schneider C; Hessmann E; Saur D; Schneider G
Cancer Metastasis Rev; 2023 Dec; 42(4):1113-1131. PubMed ID: 37659057
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic developments in pancreatic cancer.
Hu ZI; O'Reilly EM
Nat Rev Gastroenterol Hepatol; 2024 Jan; 21(1):7-24. PubMed ID: 37798442
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer.
Jiménez DJ; Javed A; Rubio-Tomás T; Seye-Loum N; Barceló C
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474109
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting Stromal Class I HDACs Curbs Pancreatic Cancer Progression.
Liang G; Oh TG; Hah N; Tiriac H; Shi Y; Truitt ML; Antal CE; Atkins AR; Li Y; Fraser C; Ng S; Pinto AFM; Nelson DC; Estepa G; Bashi S; Banayo E; Dai Y; Liddle C; Yu RT; Hunter T; Engle DD; Han H; Von Hoff DD; Downes M; Evans RM
bioRxiv; 2023 Sep; ():. PubMed ID: 37745372
[TBL] [Abstract][Full Text] [Related]
10. Histone Deacetylases (HDACs) Are Potential Biochemical Targets for Insecticide Development.
Yang JF; Shi LR; Zhang ZK; Zhou ZS; Wan FH
J Agric Food Chem; 2024 Jan; 72(2):953-955. PubMed ID: 38175159
[No Abstract] [Full Text] [Related]
11. Precision Therapy of Pancreatic Cancer: From Bench to Bedside.
Ciecielski KJ; Berninger A; Algül H
Visc Med; 2020 Oct; 36(5):373-380. PubMed ID: 33178734
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic Sequence of Histone Deacetylase Inhibitors and Radiation Treatment: An Overview.
Seane EN; Nair S; Vandevoorde C; Joubert A
Pharmaceuticals (Basel); 2024 May; 17(5):. PubMed ID: 38794172
[TBL] [Abstract][Full Text] [Related]
13. Obesity and Pancreatic Cancer: Recent Progress in Epidemiology, Mechanisms and Bariatric Surgery.
Shinoda S; Nakamura N; Roach B; Bernlohr DA; Ikramuddin S; Yamamoto M
Biomedicines; 2022 May; 10(6):. PubMed ID: 35740306
[TBL] [Abstract][Full Text] [Related]
14. The Roles of Histone Deacetylases in the Regulation of Ovarian Cancer Metastasis.
Xu L; Yan X; Wang J; Zhao Y; Liu Q; Fu J; Shi X; Su J
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894746
[TBL] [Abstract][Full Text] [Related]
15. Correlating Basal Gene Expression across Chemical Sensitivity Data to Screen for Novel Synergistic Interactors of HDAC Inhibitors in Pancreatic Carcinoma.
Djokovic N; Djuric A; Ruzic D; Srdic-Rajic T; Nikolic K
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259439
[TBL] [Abstract][Full Text] [Related]
16. Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4.
Hao S; Xu S; Li L; Li Y; Zhao M; Chen J; Zhu S; Xie Y; Jiang H; Zhu J; Wu M
BMC Cancer; 2022 Oct; 22(1):1092. PubMed ID: 36284271
[TBL] [Abstract][Full Text] [Related]
17. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review.
Koltai T; Reshkin SJ; Carvalho TMA; Di Molfetta D; Greco MR; Alfarouk KO; Cardone RA
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626089
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer.
Xiang XS; Li PC; Wang WQ; Liu L
Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188676. PubMed ID: 35016922
[TBL] [Abstract][Full Text] [Related]
19. Targeting histone deacetylases in pancreatic ductal adenocarcinoma.
Schneider G; Krämer OH; Fritsche P; Schüler S; Schmid RM; Saur D
J Cell Mol Med; 2010 Jun; 14(6A):1255-63. PubMed ID: 19929947
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
